---
document_datetime: 2025-02-18 16:39:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/balversa-epar-all-authorised-presentations_en.pdf
document_name: balversa-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9697357
conversion_datetime: 2025-12-19 02:44:39.605696
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/24/1841/003 | Balversa          | 3 mg       | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 56 tablets  |
| EU/1/24/1841/004 | Balversa          | 3 mg       | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 84 tablets  |
| EU/1/24/1841/008 | Balversa          | 4 mg       | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 28 tablets  |
| EU/1/24/1841/009 | Balversa          | 4 mg       | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 56 tablets  |
| EU/1/24/1841/011 | Balversa          | 5 mg       | Film-coated tablet    | Oral use                  | bottle (HDPE)         | 28 tablets  |